Catalys Pacific’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Catalys Pacific's MLYS Position: Q3 2026 in Review
Catalys Pacific reduced its Mineralys Therapeutics (MLYS) stake by 1.3% in Q3 2026, selling an estimated $2.84M and leaving 7,799,518 shares worth $196M. The position accounts for 93.45% of the portfolio, ranked #1.
Catalys Pacific first reported a position in MLYS in Q4 2023 and has held it in 12 quarters since. The position peaked at $338M in Q3 2025. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Catalys Pacific held 7,799,518 shares of Mineralys Therapeutics worth $196M as of Q3 2026.
- Catalys Pacific sold 104,320 Mineralys Therapeutics shares in Q3 2026, an estimated $2.84M.
- Mineralys Therapeutics made up 93.45% of Catalys Pacific's portfolio in Q3 2026, its #1 holding.
- Catalys Pacific first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Catalys Pacific's Mineralys Therapeutics position peaked at $338M in Q3 2025.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Catalys Pacific's 13F filing for Q3 2026, filed 30 Oct 2026.